Our Team

Questa's leadership team brings together world-leading scientist-entrepreneurs.
We are dedicated to transforming scientific breakthroughs into life saving treatments.

Leadership Team

Professor Sir Tony Kouzarides

FOUNDER AND CHIEF EXECUTIVE OFFICER

Professor Sir Tony Kouzarides

Sir Tony is Professor of Cancer Biology at the University of Cambridge. He is a pioneer in the field of epigenetics, following a highly successful career as a cancer researcher at the Gurdon Institute. Through his research, and a company he founded (Storm Therapeutics), a drug is currently in phase II clinical trials against cancer. Tony is the director and co-founder of the Milner Therapeutics Institute at the University of Cambridge, which drives academia/industry collaborations to progress therapies. As a serial entrepreneur, Tony is a co-founder of Abcam plc, a research reagents company, and two drug discovery companies, Chroma and STORM Therapeutics and the venture builder, Vellos. He is the founder of a cancer charity in Spain, (Vencer el Cancer) and a Venture Partner with the Fifty Years, a San Francisco-founded investor. He was knighted for “Services to Healthcare Innovation and Delivery”.

Professor François Fuks

FOUNDER AND PRESIDENT

Professor François Fuks

François is Professor of Cancer Epigenetics at the University of Brussels and Director of the Laboratory of Cancer Epigenetics. He previously served as Director of the university's Cancer Research Center, fostering collaboration between researchers and clinicians across disciplines. A pioneer in epigenetics, studying how changes to DNA and RNA control how genes work, his research has transformed our understanding of how cancers develop and respond to treatment. Following a PhD at the German Cancer Research Center in Heidelberg and postdoctoral researcher at the University of Cambridge, he established an internationally recognised research programme in cancer epigenetics. As both a scientist and entrepreneur, François co-founded EPICS Therapeutics to translate discoveries in RNA epigenetics into new cancer medicines. The company's lead programme has now entered clinical trials in cancer patients. Overall, his career combines scientific discovery and entrepreneurship with a strong commitment to turning science into healthcare innovation.

Raj Mehta

Chief Scientific Officer

Raj Mehta

At Questa, Raj leads the company’s scientific strategy. He is also Founder, CEO and Director of Adendra Therapeutics and Non-Executive Director of Revitope Oncology Inc. Raj has over 20 years’ experience partnering early-stage technologies and forming biotech companies. He spent 18 years at Cancer Research Technology, the commercialisation and development arm of Cancer Research UK, where he led portfolio management of biological and small molecule therapeutic assets and helped create companies including BliNK Therapeutics, Revitope and GammaDelta Therapeutics. He served as interim CEO of GammaDelta Therapeutics, establishing a partnership with Takeda, and previously led drug discovery groups at the E. Merck Laboratory at the MRC Collaborative Centre in London, supporting anti-angiogenesis and cardiovascular programmes for Merck KGaA.

Dr Louise Mason

Chief Operating Officer

Dr Louise Mason

Louise leads operations and programme delivery at Questa. She is also Director of Global Programmes (Vellos) and Innovation Affiliate in the Advanced Research Centre (University of Glasgow, UofG). She holds a Master's degree in Chemistry with Drug Discovery and a PhD in Biomedical Engineering, spending over a decade translating scientific research into commercial, clinical and societal impact. In 2018, Louise was decorated in Parliament with the Westminster Medal for Excellence in Engineering. She has also worked in spin-outs in the UK and US. Previously, she was Head of Innovation & Enterprise and Chair of the Translational Research Initiative Management Team (UofG), managing large research portfolios, supporting the creation of deep-tech ventures, and developing partnerships that accelerated the advancement of novel technologies from discovery to application.

Challenge Solution Partners

Ad Atomica logoo2h discovery logoBioMed X logoVellos logo

Start here

Bring your challenge into focus.

We welcome conversations with pharma, biotech, charities, investors and researchers exploring new approaches to healthcare challenges.